Abstract
Osteoporosis is characterised by excess bone fragility resulting from bone loss and altered bone microarchitecture. Bone loss occurring during aging and after menopause in women is known to result from an imbalance between bone formation and resorption. Bone formation is dependent on the commitment of osteoprogenitor cells, the proliferation of pre-osteoblasts, their differentiation into mature osteoblasts synthesising bone matrix and the life-span of mature osteoblasts. Transforming Growth Factor ß (TGFß) and Fibroblast Growth Factors (FGFs) are important factors that promote osteoprogenitor cell proliferation and osteogenesis. Reduced expression of TGFß in bone was found in several animal models of osteopenia. In addition, both FGF and TGFß were found to exert anabolic effects on bone formation in intact animals and to reduce bone loss in experimental models of osteoporosis. Both genetic manipulation of FGF and TGFß or their receptors in mice and bone phenotype associated with FGF receptors and TGFß mutations or polymorphism suggest that TGFß and FGF signalling may contribute to the control of osteogenesis and bone mass in vivo. The determination of molecular mechanisms involved in the anabolic actions of FGF and TGFß in cells of the osteoblastic lineage may lead in the future to the development of new therapeutic strategies aimed at improving bone formation in osteoporotic patients.
Keywords: fgf, osteoblast, osteopenia, aging
Current Pharmaceutical Design
Title: Growth Factors and Bone Formation in Osteoporosis: Roles for Fibroblast Growth Factor and Transforming Growth Factor Beta
Volume: 10 Issue: 21
Author(s): Olivia Fromigué, Dominique Modrowski and Pierre J. Marie
Affiliation:
Keywords: fgf, osteoblast, osteopenia, aging
Abstract: Osteoporosis is characterised by excess bone fragility resulting from bone loss and altered bone microarchitecture. Bone loss occurring during aging and after menopause in women is known to result from an imbalance between bone formation and resorption. Bone formation is dependent on the commitment of osteoprogenitor cells, the proliferation of pre-osteoblasts, their differentiation into mature osteoblasts synthesising bone matrix and the life-span of mature osteoblasts. Transforming Growth Factor ß (TGFß) and Fibroblast Growth Factors (FGFs) are important factors that promote osteoprogenitor cell proliferation and osteogenesis. Reduced expression of TGFß in bone was found in several animal models of osteopenia. In addition, both FGF and TGFß were found to exert anabolic effects on bone formation in intact animals and to reduce bone loss in experimental models of osteoporosis. Both genetic manipulation of FGF and TGFß or their receptors in mice and bone phenotype associated with FGF receptors and TGFß mutations or polymorphism suggest that TGFß and FGF signalling may contribute to the control of osteogenesis and bone mass in vivo. The determination of molecular mechanisms involved in the anabolic actions of FGF and TGFß in cells of the osteoblastic lineage may lead in the future to the development of new therapeutic strategies aimed at improving bone formation in osteoporotic patients.
Export Options
About this article
Cite this article as:
Fromigué Olivia, Modrowski Dominique and Marie J. Pierre, Growth Factors and Bone Formation in Osteoporosis: Roles for Fibroblast Growth Factor and Transforming Growth Factor Beta, Current Pharmaceutical Design 2004; 10 (21) . https://dx.doi.org/10.2174/1381612043383773
DOI https://dx.doi.org/10.2174/1381612043383773 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preclinical and Clinical Efficacy of the Bisphosphonate Ibandronate in Cancer Treatment
Current Clinical Pharmacology A Brief Introduction to Porphyrin Compounds used in Tumor Imaging and Therapies
Mini-Reviews in Medicinal Chemistry Therapeutic Prospects for Parathyroid Hormone and Parathyroid Hormone Analogs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Gene Therapy for Osteoinduction
Current Gene Therapy Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets Regulation of Iron Absorption in Hemoglobinopathies
Current Molecular Medicine The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Endocrine, Metabolic & Immune Disorders - Drug Targets Malignant Hypercalcemia
Current Medicinal Chemistry The Role of Binding Kinetics in GPCR Drug Discovery
Current Topics in Medicinal Chemistry The Anabolic Effects of Growth Hormone (GH) and GH Secretagogues on Bone Mass and Density
Medicinal Chemistry Reviews - Online (Discontinued) Vitamin D and Lung Cancer
Current Respiratory Medicine Reviews TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design Osteoclasts and Remodeling Based Bone Formation
Current Stem Cell Research & Therapy Physical Means of Stratum Corneum Barrier Manipulation to Enhance Transdermal Drug Delivery
Current Drug Delivery New and Emerging Antiresorptive Treatments in Osteoporosis
Current Drug Safety Nutritional Modulation of Terminal End Buds: Its Relevance to Breast Cancer Prevention
Current Cancer Drug Targets Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Current Molecular Medicine